Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, and Histone Deacetylase Inhibitors Research.
Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT.
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.
Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma.
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party.
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT
Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group
Sensitization of Non‐<scp>M3</scp> Acute Myeloid Leukemia Blasts to All‐<i>Trans</i> Retinoic Acid by the <scp>LSD1</scp> Inhibitor Tranylcypromine: <scp>TRANSATRA</scp> Phase I Study
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMT
Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary <scp>AML</scp> in First Complete Remission: A Study From the <scp>ALWP</scp> / <scp>EBMT</scp>
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms
The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13).
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party.
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMT.
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.
Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis.
Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWP
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study.